$4.29 Billion in Sales Expected for Novo Nordisk A/S (NYSE:NVO) This Quarter
Analysts forecast that Novo Nordisk A/S (NYSE:NVO) will post sales of $4.29 billion for the current quarter, according to Zacks. Two analysts have made estimates for Novo Nordisk A/S’s earnings, with the highest sales estimate coming in at $4.38 billion and the lowest estimate coming in at $4.20 billion. Novo Nordisk A/S reported sales of $4.17 billion in the same quarter last year, which would suggest a positive year over year growth rate of 2.9%. The business is expected to announce its next quarterly earnings report on Wednesday, August 9th.
On average, analysts expect that Novo Nordisk A/S will report full-year sales of $4.29 billion for the current financial year, with estimates ranging from $17.10 billion to $17.55 billion. For the next financial year, analysts expect that the business will report sales of $17.42 billion per share, with estimates ranging from $16.90 billion to $17.95 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Novo Nordisk A/S.
Several research analysts recently weighed in on the company. BidaskClub raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, June 15th. Zacks Investment Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research report on Wednesday, June 21st. Finally, TheStreet raised Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Five research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $53.00.
COPYRIGHT VIOLATION NOTICE: “$4.29 Billion in Sales Expected for Novo Nordisk A/S (NYSE:NVO) This Quarter” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/11/4-29-billion-in-sales-expected-for-novo-nordisk-as-nysenvo-this-quarter.html.
Shares of Novo Nordisk A/S (NYSE NVO) opened at 44.15 on Friday. Novo Nordisk A/S has a 52-week low of $30.89 and a 52-week high of $47.98. The stock has a market cap of $110.19 billion, a P/E ratio of 18.16 and a beta of 0.63. The firm has a 50-day moving average price of $42.69 and a 200-day moving average price of $38.73.
The company also recently declared an annual dividend, which will be paid on Tuesday, August 29th. Investors of record on Monday, August 21st will be paid a $0.336 dividend. This represents a yield of 1.07%. This is an increase from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date is Friday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 35.84%.
A number of institutional investors have recently bought and sold shares of the company. Guggenheim Capital LLC increased its position in Novo Nordisk A/S by 4.3% in the fourth quarter. Guggenheim Capital LLC now owns 35,235 shares of the company’s stock worth $1,264,000 after buying an additional 1,442 shares during the period. Creative Planning increased its position in Novo Nordisk A/S by 63.3% in the first quarter. Creative Planning now owns 40,622 shares of the company’s stock worth $1,393,000 after buying an additional 15,746 shares during the period. Bank of Montreal Can increased its position in Novo Nordisk A/S by 64.7% in the first quarter. Bank of Montreal Can now owns 65,178 shares of the company’s stock worth $2,234,000 after buying an additional 25,611 shares during the period. Gradient Investments LLC increased its position in Novo Nordisk A/S by 317.7% in the first quarter. Gradient Investments LLC now owns 7,590 shares of the company’s stock worth $260,000 after buying an additional 5,773 shares during the period. Finally, Capstone Asset Management Co. increased its position in Novo Nordisk A/S by 5.8% in the first quarter. Capstone Asset Management Co. now owns 76,085 shares of the company’s stock worth $2,608,000 after buying an additional 4,170 shares during the period. Institutional investors and hedge funds own 6.40% of the company’s stock.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.